It’s the beginning of the year—an opportune time to forecast how 2011 will unfold in healthcare. We are likely to see some surprises, such as the sharply rising importance of primary care physicians. Here are some predictions about the new year: • More consolidation is on its way in healthcare under Obamacare, which heightens the … Continue reading “How 2011 Will Unfold in Healthcare”
Author: John Steuart
John Steuart is Managing Director at Claremont Creek Ventures in Oakland, CA. John has spent the last 20 years managing, building and investing in technology and life science companies. John focuses on the intersection of the information technology and life sciences markets including bioinformatics, molecular diagnostics, genomics, proteomics, software and instrumentation for med-tech industries.
John serves on the board of directors of Arcxis, Tibion, Fluxion, Gene Security Network and Wired Benefits. He is an Industry Fellow at the Center for Entrepreneurship and Technology at the College of Engineering as well as a member of the Advisory Council to the Lester Center's Berkeley Entrepreneurs' Forum at UC Berkeley.
Early in his career, he joined Alafi Capital, an Emeryville-based venture firm specializing in early-stage biomedical companies, where he served as an officer of the General Partner. At Alafi, John lead investments in more than a dozen successful start-ups, and served as the senior executive and board member of various firms such as Tanox, Software Ventures, Lipomatrix and Megan Health.
In the mid-90s, together with colleague Nat Goldhaber, John helped start Cybergold, an Internet marketing and payments company, serving as the early COO and CFO through its IPO, merger with Mypoints and sale to United Airlines. John continued with the Mypoints unit of United serving as the Senior Vice President of Strategic Partnerships.
John lives in Berkeley with his wife and three children, a block away from the Triple Rock brewery.
How VCs Use Advice from Experts
In recent years, doctors, scientists, and experts who consult with pharmaceutical companies and hedge funds have come under increasing scrutiny from the media and their fellow professionals. The truth is, it’s a case of caveat emptor—both for the experts and for the organizations hiring them. Biotech or medical device companies that are trying to promote … Continue reading “How VCs Use Advice from Experts”